Median Technologies FR0011049824, ALMDT, PEA/PME eligible, “Median” or “The Company” will hold two web conferences on Thursday, September 5, 2024.
Following the recent communication of the results of the REALITY study of eyonis™ LCS, Fredrik Brag, CEO and Founder of Median, will return to this announcement, on the challenges related to eyonis™ LCS, and will present the next steps concerning the new medical device software from Median.
- September 5, 2024: Webconference (English) at 4:00 p.m. CEST
- September 5, 2024: Webconference (French) at 6:00 p.m. CEST:
Replays of the web conferences will be available online on the Median Technologies website shortly after the live presentations.
Also Read: IBM Processor Innovations for AI on Next-Gen Z Mainframes
A pioneer in innovative imaging solutions and services, Median Technologies leverages cutting-edge Artificial Intelligence technologies to increase the accuracy of early diagnosis and treatment of many cancers. Median’s offerings, iCRO for the analysis and management of medical images in oncology clinical trials and eyonis™, a suite of medical device software based on AI and machine learning technologies, enable biopharmaceutical companies and clinicians to advance patient care and accelerate the development of new therapies. The French company, also present in the United States and China, is listed on the Euronext Growth market (ISIN: FR0011049824, MNEMO: ALMDT). Median Technologies is eligible for the PEA-PME.
SOURCE: Businesswire